Accent Therapeutics Advances ATX-295 at ASCO
LEXINGTON, Mass., May 21, 2026 Accent Therapeutics has announced the presentation of a Trial in Progress poster for its...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
LEXINGTON, Mass., May 21, 2026 Accent Therapeutics has announced the presentation of a Trial in Progress poster for its...
INGELHEIM, Germany & RIDGEFIELD, Conn., May 21, 2026 Boehringer Ingelheim has unveiled significant new oncology data at the 2026...
